A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
Status:
Completed
Trial end date:
2017-08-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the intrapulmonary penetration of nacubactam in
healthy volunteers. Nacubactam is a novel non-beta-lactam beta-lactamase inhibitor being
developed as a combination therapy with the beta-lactam meropenem for the treatment of
serious gram-negative bacterial infections. Adult male and female healthy participants will
receive a single intravenous infusion of nacubactam co-administered with meropenem and then
undergo a bronchoalveolar lavage (BAL) procedure to collect lung epithelial lining fluid
(ELF) for measurement of intrapulmonary concentrations of nacubactam and meropenem.